Regenerative and immunotherapy support for patients in active treatment or recovery, designed to work alongside your primary oncology team. The focus is immune function, recovery, and quality of life.
By Jed Ryan, Founder and CEO · Reviewed by Adas Darinskas, PhD, Chief Science Officer · Published · Last reviewed
Conventional cancer treatment (surgery, chemotherapy, radiation) relies on chemical and physical agents whose action on cancer cells is rarely fully selective, so healthy tissue is affected too. The immune system, already strained by the disease, is suppressed further by the treatment meant to fight it. The question we work on is what can be done alongside conventional care to support the body through and after that treatment.
Immunotherapy works in two directions. It can stimulate an underactive immune system, as in oncology, where the body’s natural response to cancer cells has become insufficient. It can also calm an overactive one, as in autoimmune disease. For oncology support, the goal is to strengthen immune response. The tools are biologically active molecules the body produces naturally, or the patient’s own immune cells expanded and activated outside the body.
We coordinate adjunctive care for patients in the following contexts:
All treatment decisions are made in coordination with the patient’s primary oncology team. Adjunctive care is layered onto an existing treatment plan, not substituted for one.
Even the best-tolerated cancer treatment puts pressure on systems the patient still depends on for recovery. The biology behind “treatment fatigue” is concrete:
Cancer itself disrupts immune surveillance, and chemotherapy and radiation depress immune cell counts and function further. So the patient is fighting the cancer with an immune system that the treatment has weakened.
Chemotherapy targets rapidly dividing cells, and it cannot tell one tissue type from another. Bone marrow, gut lining, hair follicles, and other fast-dividing tissues get hit, and that accounts for much of the treatment burden.
The disease, the treatment, and the systemic stress of both produce a sustained inflammatory environment that impairs healing and quality of life.
Cellular energy capacity falls during and after intensive treatment, contributing to fatigue, slow recovery, and prolonged convalescence.
The natural killer (NK) cell and T-cell populations responsible for ongoing immune monitoring of abnormal cells often run depleted or exhausted post-treatment.
Adjunctive regenerative care works on these supporting systems, not on the cancer itself, so the body has more capacity to respond to whatever conventional protocol is in progress.
The modalities below work through three main mechanisms. Each one supports conventional treatment rather than replacing it.
Specific immune cell populations (dendritic cells, natural killer cells) can be isolated from the patient, expanded and activated outside the body, then reintroduced. The aim is to rebuild immune capacity that disease and treatment have suppressed.
Cytokines, interferons, and antibodies are molecules the body makes under normal conditions. Used therapeutically, they support immune function during and after conventional treatment, working in the same pathways the body itself uses.
Cellular and peptide therapies, layered with metabolic IV support, address the tissue damage and depleted energy reserves that conventional treatment leaves behind. The aim is faster, more complete recovery between treatment cycles.
We are careful about what we claim. The clinical evidence for these modalities sits at different stages, and individual response varies widely. We describe how each one works, we do not promise outcomes, and we coordinate every case with the patient’s oncology team.
Each protocol is designed by our medical team in coordination with the patient’s primary oncology team, based on the specific cancer, treatment phase, and individual context. The modalities below are the building blocks most often deployed.
Dendritic cells are the immune system’s antigen-presenting messengers: they train other immune cells to recognize specific threats. In dendritic cell vaccine protocols, the patient’s own dendritic cells are isolated, exposed to tumor-associated antigens outside the body, and reintroduced. The aim is to prime the immune system to recognize and respond to specific cancer cell markers.
An emerging area of clinical investigation in adjunctive oncology care, with a growing body of preclinical and early-phase clinical work supporting its mechanism. Used adjunctively to conventional treatment, never as a replacement.
Natural killer (NK) cells are part of the body’s innate immune surveillance, the population that recognizes and removes abnormal cells. In NK cell therapy, the patient’s NK cells are isolated, expanded in number, and activated with cytokines outside the body, then reinfused.
Peer-reviewed research and ongoing clinical trials are looking at their adjunctive role in oncology care across multiple cancer types. As with everything here, the role is supportive: layered onto a primary treatment plan, never substituted for one.
Biological therapy uses biologically active molecules the body makes naturally, such as cytokines, interferons, and antibodies, to support immune function during and after conventional treatment. These molecules act in the same pathways the body itself uses to coordinate immune response.
Specific protocols are built case by case in coordination with the patient’s oncology team, with the goal of supporting immune capacity through periods when conventional treatment is most depressing it.
Recovery-focused care designed to help the body restore function and reduce side effects following chemotherapy. Includes nutritional, infusion-based, and tissue-recovery support delivered through the partnered clinical setting.
The intent is concrete: faster bone-marrow recovery between cycles, reduced gastrointestinal and mucosal damage, improved energy and cognitive recovery, and broader quality-of-life support during a demanding treatment course.
Physical rehabilitation and movement therapy adapted specifically for patients during and after cancer treatment. Strength, mobility, and recovery of function are addressed deliberately rather than left to general fitness advice.
Delivered by clinicians trained in the specific demands of oncology rehabilitation, with treatment intensity calibrated to where the patient is in their treatment timeline.
Targeted peptide protocols selected to support immune function, energy, recovery, and overall quality of life during and after conventional oncology treatment. The peptide stack is built case by case, never generic, and always coordinated with the rest of the treatment plan.
The framing here is the same as elsewhere on this page: supportive, adjunctive, and explicit about the boundaries between what regenerative tools can and cannot do.
Every protocol is coordinated with the patient’s oncology team. We do not advise patients to delay, modify, or stop conventional treatment. We provide adjunctive support designed to make conventional treatment more tolerable and recovery more complete.
Strong Craft Regen keeps a current library of peer-reviewed research on regenerative medicine: the studies, mechanisms, and ongoing investigations that inform every protocol we coordinate.
Explore the Research